肾素-血管紧张素系统抑制药和糖尿病

被引：10

作者：

黄震华

机构：

[1] 上海交通大学医学院附属第九人民医院心血管病研究室

来源：

中国新药与临床杂志 | 2011年 / 30卷 / 01期

关键词：

血管紧张素转换酶抑制药; 血管紧张素Ⅱ1型受体拮抗剂; 糖尿病;

D O I：

暂无

中图分类号：

R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

血管紧张素转换酶抑制药(ACEI)和血管紧张素Ⅱ受体1拮抗药(ARB)是目前抑制肾素-血管紧张素系统的主要药物大量研究结果表明ACEI和ARB不仅可降低糖尿病的发生率、延迟糖尿病的进展,而且可降低糖尿病患者心血管事件的发生率和心血管死亡率。本文对其作用及机制进行探讨

引用

页码：11 / 15

页数：5

共 9 条

[1]

Prevention of diabetes and cardiovascular' disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial [J].

Califf, Robert M. ;

Boolell, Mitradev ;

Haffner, Steven M. ;

Bethel, M. Angelyn ;

McMurray, John ;

Duggal, Anil ;

Holman, Rury R. .

AMERICAN HEART JOURNAL, 2008, 156 (04) :623-632

[2]

Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering [J].

Karalliedde, Janaka ;

Smith, Andrew ;

DeAngelis, Lorenita ;

Mirenda, Vincenzo ;

Kandra, Albert ;

Botha, Jaco ;

Ferber, Philippe ;

Viberti, Giancarlo .

HYPERTENSION, 2008, 51 (06) :1617-1623

[3]

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial [J].

Patel, A. ;

MacMahon, S. ;

Chalmers, J. ;

Neal, B. ;

Woodward, M. ;

Billot, L. ;

Harrap, S. ;

Poulter, N. ;

Marre, M. ;

Cooper, M. ;

Glasziou, P. ;

Grobbee, D. E. ;

Hamet, P. ;

Heller, S. ;

Liu, L. S. ;

Mancia, G. ;

Mogensen, C. E. ;

Pan, C. Y. ;

Rodgers, A. ;

Williams, B. .

LANCET, 2007, 370 (9590) :829-840

[4]

Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes [J].

Willemsen, Judith M. ;

Westerink, Jan W. ;

Dallinga-Thie, Geesje M. ;

van Zonneveld, Anton-Jan ;

Gaillard, Carlo A. ;

Rabelink, Ton J. ;

de Koning, Eelco J. P. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (01) :6-12

[5]

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].

Julius, S ;

Kjeldsen, SE ;

Weber, M ;

Brunner, HR ;

Ekman, S ;

Hansson, L ;

Hua, TS ;

Laragh, J ;

McInnes, GT ;

Mitchell, L ;

Plat, F ;

Schork, A ;

Smith, B ;

Zanchetti, A .

LANCET, 2004, 363 (9426) :2022-2031

[6]

Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) [J].

Lindholm, LH ;

Persson, M ;

Alaupovic, P ;

Carlberg, B ;

Svensson, A ;

Samuelsson, A .

JOURNAL OF HYPERTENSION, 2003, 21 (08) :1563-1574

[7]

Effects of candesartan on mortality and morbidity in patients with chronic heart failure:: the CHARM-Overall programme [J].

Pfeffer, MA ;

Swedberg, K ;

Granger, CB ;

Held, P ;

McMurray, JJV ;

Michelson, EL ;

Olofsson, B ;

Östergren, J ;

Yusuf, S .

LANCET, 2003, 362 (9386) :759-766

[8]

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[9]

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:: the Captopril Prevention Project (CAPPP) randomised trial [J].

Hansson, L ;

Lindholm, LH ;

Niskanen, L ;

Lanke, J ;

Hedner, T ;

Niklason, A ;

Luomanmäki, K ;

Dahlöf, B ;

de Faire, U ;

Mörlin, C ;

Karlberg, BE ;

Wester, PO ;

Björck, JE .

LANCET, 1999, 353 (9153) :611-616

← 1 →